YCT 529
Alternative Names: YCT-529Latest Information Update: 01 Oct 2024
At a glance
- Originator University of Minnesota
- Developer YourChoice Therapeutics
- Class Benzene derivatives; Benzoic acids; Benzopyrans; Contraceptives; Pyrroles; Small molecules
- Mechanism of Action Retinoic acid receptor alpha antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Pregnancy
Most Recent Events
- 11 Sep 2024 Phase-I/II clinical trials in Pregnancy (Prevention) in New Zealand (PO) (NCT06542237)
- 12 Aug 2024 YourChoice Therapeutics plans a phase Ib/IIa trial in Healthy volunteers (PO) in August 2024 (NCT06542237)
- 04 Jun 2024 YourChoice Therapeutics completes a phase I trial in Pregnancy (Prevention) in United Kingdom (PO) (NCT06094283)